Back to the news

OncoDNA reinforces its presence in the United Kingdom by appointing a Medical Director, Dr Philip Beer 

Dr. Beer decided to work hand in hand with OncoDNA

UK, 10th of January 2018 – OncoDNA announces the appointment of a Medical Director in the United Kingdom, Dr. Philip Beer, Physician Scientist and precision oncology specialist. From now on, the conclusions of OncoDNA’s analyses reports will be reviewed and validated by Dr. Beer. He will also contact personally the oncologists to discuss the report with them.

Recognizing that precision medicine can greatly assist oncologists in choosing treatments for patients with advanced cancer, Dr. Beer decided to work hand in hand with OncoDNA. The goal is to lead the way in demonstrating the effectiveness of this technology and ensuring that more patients have access to it. Since September 2017, major health insurers have approved reimbursement in the United Kingdom for OncoSTRAT&GO, the most complete solution from OncoDNA which enables oncologists to find the most appropriate treatment options for each cancer patient.

Dr Philip Beer operates across the academic, healthcare and private sectors, with the singular goal of leveraging genomic technologies to improve outcomes for cancer patients. His specific interests include clinical implementation of cancer genomic platforms, alongside interpretation of the output data for use in routine oncology practice. Philip trained as a hematologist at Imperial College, London, followed by academic research at the University of Cambridge and the BC Cancer Agency, Vancouver. His current roles include working as a molecular and cellular pathologist at a flagship NHS diagnostic unit, translational support for early clinical stage oncology drug development with a small pharmaceutical company, and involvement in academic research projects encompassing cancer genomics and functional modeling.